NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









iQure Pharma

iQure Pharma

Private
Princeton, New JerseyHealthcare & Life Scienceshttps://www.iqurepharma.com/

Last Round

Seed Round

Jun 3, 2026

Total Funding Raised

$7.6M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

iQure Pharma is a biotechnology company that develops innovative therapeutics for central nervous system disorders by restoring glutamate homeostasis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyCNS disorderssmall molecule therapeuticsdrug discoveryEAAT2 modulatorbiotech startupclinical-stage biotechcentral nervous systemout-licensingexcitotoxicityneurodegenerationdrug pipelineepilepsy treatmentpharma partneringbiotech pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

iQure Pharma Comparables

Compare iQure Pharma with similar companies based on industry and business-model similarity.

iQure Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mentara Bio Inc.
86%
GliaPharm SA
80%
Astrocyte Pharmaceuticals Inc.
75%

iQure Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundJun 3, 2026
Series BJan 7, 2025
Series ANov 28, 2023
Series AOct 23, 2023
Series ASep 1, 2022

Key People

Founding team and executive leadership

Henk De Wilde

Chief Development Officer, Chief Operating Officer

Executive Team

iQure Pharma Investors

Notable investors and investment history

iQure Pharma investors
InvestorRounds
OKG CapitalSeries A, Series B
Ventura BioMed InvestorsSeries A
Keiretsu Forum Mid-AtlanticSeries A
i&i PragueSeries B
Mass Medical AngelsSeries A
Ventura BioMedicalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 3, 2026

    $650K raised in Seed Round.

  • Jul 2, 2025

    Prof. Dr. Iris Loew-Friedrich appointed as advisor.

iQure Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

iQure Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about iQure Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersPrinceton, New Jersey
Employee Range9
Year Founded2019
Last FundingJun 3, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.